Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Companies to evaluate a two-drug combination of Medivir/Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational ...
Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it has appointed...
- All TMC435 Patient Subgroups Achieved Substantially Higher SVR4 Rates (Undetectable Virus 4 Weeks After End of Treatment) Compared to...
Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.